BCTXZ

NASD BriaCell Therapeutics Corp. - Warrant
Oct 3, 2026 · 6:59 PM ET EOD Market Closed

$0.2980 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.2980, and at the day’s high of $0.2999

YTD change
+2.69%
vs 20-day SMA
+76.94%
vs 200-day SMA
+93.63%

Price ranges

Previous day
$0.1844 $0.2999
open $0.2900 close $0.2980
+$0.0080 (+2.76%)
Today
$0.1844 $0.2999
$0.2980
Past week
$0.1403 $0.2320
from $0.2000 now $0.2980
+$0.0980 (+49.00%)
Past month
$0.1019 $0.2647
from $0.1870 now $0.2980
+$0.1110 (+59.36%)
This year
$0.0551 $0.3831
from $0.2902 now $0.2980
+$0.0078 (+2.69%)

Price & Performance

+0.16 (+108.98%) / 6M

$0.0616$0.1462$0.2309$0.3155Apr 6Jul 6Oct 2

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 80.3% away from all-time highs of $1.5150
  • BCTXZ is up 3% since the beginning of the year
  • BCTXZ is down 26% over the past 12 months
  • BCTXZ is up 59% over the past 1 month

BCTXZ reads very good: price sits above both the 20- and 200-day averages, the 12-month move is -33.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-84.0199
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A

Balance sheet & scale

IncomeN/A
RevenueN/A
CashN/A
DebtN/A
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap N/A

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $403.04 -1.04%
MRNA Moderna, Inc. $190.01 +0.57%
RVMD Revolution Medicines, Inc. $206.64 +0.36%
ROIV Roivant Sciences Ltd. $35.72 +0.62%
BNTX BioNTech SE Sponsored ADR $96.90 +0.05%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.